RG-6351
- Generic Name
- RG-6351
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Phase 1
Recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 546
- Registration Number
- NCT06850922
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Phoenix, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸Associated Retinal Consultants PC, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath